The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.

ABSTRACT: BACKGROUND:The European Randomized Study of Screening for Prostate Cancer (ERSPC) demonstrated that prostate-specific antigen (PSA) screening significantly reduced prostate cancer mortality (rate ratio, 0.79; 95% confidence interval, 0.69-0.91). The US Prostate, Lung, Colorectal, and Ovarian (PLCO) trial indicated no such reduction but had a wide 95% CI (rate ratio for prostate cancer mortality, 1.09; 95% CI, 0.87-1.36). Standard meta-analyses are unable to account for key differences between the trials that can impact the estimated effects of screening and the trials' point estimates. METHODS:The authors calibrated 2 microsimulation models to individual-level incidence and mortality data from 238,936 men participating in the ERSPC and PLCO trials. A cure parameter for the underlying effic

SUBMITTER: de Koning HJ 

PROVIDER: S-EPMC5839977 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature